By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel agrees that high in-network denial rates for prior-authorized scans (19%) can lead to delayed diagnoses, increased long-term treatment costs, and potential regulatory pressure on insurers. The key debate lies in whether these denials are medically justified or profit-driven.
Risk: Regulatory or political pressure if a pattern emerges that guideline-concordant imaging is systematically under-approved, potentially leading to unintended access harm.
Opportunity: Improved data collection and transparency to distinguish between legitimate medical reviews and inappropriate denials.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Despite having the highest health spending in the industrialized world, the U.S. has some of the worst health outcomes (1).
A 2025 report from the Peterson Center on Healthcare (2) and KFF (3) projected that Americans would spend $5.6 trillion on health care (4) for the year — and that number is expected to continue growing to a possible $8.6 trillion by 2033. Yet the high cost of care, delays in treatment and fragmented insurance coverage have left many patients across the country vulnerable.
- Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
- Robert Kiyosaki says this 1 asset will surge 400% in a year and begs investors not to miss this ‘explosion’
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s how to fix it ASAP
Rebecca Payette is a prime example. In an interview with WCVB (5), the Virginia woman says she's now battling stage 4 cancer after her insurance denied a critical PET scan.
Payette began experiencing constant fatigue nearly two years ago, but doctors initially thought it was COVID-19 despite her never testing positive. In 2024, she says a spot was found on her lung during an annual checkup. Her doctor suggested a scan.
"So, he fixed it up, put it at the end of the referral, got to my paperwork and was supposed to go for the scan. The insurance company denied it," Payette said. She noted that she was told the lesion in her lung wasn’t big enough.
Since no one seemed too worried about it, Payette let it go.
It wasn't until a year later, when another doctor approved the scan, that everything changed. She was diagnosed with Stage IV metastatic adenocarcinoma (6), an aggressive form of lung cancer. Without treatment, doctors told her she likely had just two years to live.
"I feel like they signed my death certificate; I really did," Rebecca Payette said.
Payette now makes a nearly two-hour drive every week, from Virginia to North Carolina, for treatment.
The most recent data on health care (7) rejections found that in 2023, health insurance exchange carriers rejected nearly one-in-five in-network claims. Out-of-network claims were denied at 37%.
The study also found denial rates differed based on coverage. People with marketplace insurance reported higher rates of denial, compared to individuals with Medicare or Medicaid.
The reason claims are rejected varies. Denials can happen when patients have reached their benefit limits, if a procedure is excluded from coverage or if it's seen as investigational or experimental.
Four leading AI models discuss this article
"Rising regulatory and litigation risk around oncology denials will compress margins for managed-care names more than the market currently prices in."
The story illustrates how insurance prior-authorization denials can convert early-stage findings into stage-4 diagnoses, driving up lifetime treatment costs that ultimately hit payers and employers. At 19% in-network denial rates and $5.6 trillion in 2025 national health spending, these episodes increase political pressure for tighter MA oversight and faster appeals processes. Health insurers could face higher loss ratios if regulators mandate coverage for borderline PET scans or impose penalties for overturned denials.
The initial denial may have followed strict size-based NCCN criteria for PET imaging of sub-centimeter nodules; retrospective outrage ignores that most such lesions are benign and that approving every request would raise premiums for everyone.
"Denial rates are genuinely elevated and politically vulnerable, but this article's framing obscures whether the problem is denials of *appropriate* care or denials of *inappropriate* care—a critical distinction for valuing insurers and predicting regulatory risk."
This article conflates two separate problems: systemic denial rates (19% in-network, 37% out-of-network in 2023) with a single anecdotal case. The denial data is real and troubling, but the article doesn't distinguish between legitimate medical review (lesion size thresholds exist for reason—small nodules have low cancer probability) and inappropriate denials. The Virginia case is emotionally compelling but medically ambiguous: was the initial denial medically defensible? Did the lesion actually grow, or was it missed on first scan? The article also omits that insurers face adverse selection pressure—if they approve every low-probability scan, premiums rise for everyone. The real story isn't that denials happen; it's whether denial *rates* have risen, whether appeals succeed (not stated), and whether the threshold-setting is evidence-based or profit-driven.
Payette's case may reflect appropriate gatekeeping: sub-5mm lung nodules have <1% malignancy risk, and PET scans are expensive and have false-positive rates. The article never establishes the lesion size, growth trajectory, or whether her doctor appealed the denial—suggesting either the case was weaker than presented or the outlet didn't investigate thoroughly.
"Aggressive utilization management is creating a 'hidden liability' for insurers by delaying diagnoses that ultimately result in more expensive, late-stage claims."
The narrative of 'insurer greed' overshadows the systemic issue of administrative friction in US healthcare. While the 18-20% denial rate for in-network claims cited is alarming, it reflects a defensive posture against rising medical loss ratios (MLRs) and the over-utilization of high-cost diagnostics. For insurers like UnitedHealth (UNH), this is a margin-preservation strategy, but it creates a massive liability for the healthcare system: delayed diagnosis increases long-term treatment costs exponentially. We are seeing a shift where payers prioritize short-term cost containment over actuarial risk management, effectively offloading the financial burden onto the patient and the provider's future liability, which is unsustainable for the broader managed care sector.
The strongest case against this is that insurers are acting as the only check on runaway medical inflation; without strict utilization review (UR), the $5.6 trillion spend would likely accelerate even faster due to unnecessary testing.
"The article's case is alarming but not evidence of systemic insurer failure; denials often reflect guideline-based decisions, prior-authorization constraints, and access disparities rather than universal delays in cancer diagnosis."
One vivid case does not equal a systemic flaw, but it spotlights how prior-authorization and coverage exclusions can delay care in oncology. The article cites 2023 denial rates of about 20% in-network and 37% out-of-network, yet it offers no view of plan details, clinical guidelines, or whether the PET scan was guideline-suggested for that lesion size. If this is an isolated misstep, the market impact is muted; if it signals broader access frictions, reform could pressure margins for insurers and accelerate demand for imaging alternatives or streamlined approvals. Geographic disparities and patient advocacy dynamics also matter for who bears the cost and timing of diagnosis.
That said, correlation does not prove causation; many pulmonary nodules are indeterminate, and a denial today may reflect guideline-driven care rather than negligence—so the case may overstate systemic failure.
"Guideline-based denials risk broader regulatory intervention affecting insurer margins via employer and political pressures."
Claude overlooks how even guideline-based denials for sub-centimeter nodules can trigger systemic backlash when they progress to advanced cancer, as in Payette's case. This amplifies calls for MA reform beyond individual appeals, potentially forcing UnitedHealth and peers to absorb higher imaging volumes. The omitted factor is employer pushback on rising premiums from such delays, which could erode MLR flexibility faster than profit-driven thresholds suggest.
"Employer backlash works through plan selection, not regulatory reform; the threat is member defection, not forced coverage mandates."
Grok conflates employer pressure with regulatory mandate—two different forces. Employers care about total cost of care and employee satisfaction, not MA reform ideology. If Payette's delayed diagnosis costs her employer $2M in lifetime treatment versus $500 for an upfront PET, the math favors approval. But that's individual case economics, not systemic policy. The real lever is whether *repeated* denials of guideline-concordant scans erode trust enough to shift enrollment away from restrictive MA plans—which would hit UNH's volume, not necessarily MLR.
"Aggressive utilization review risks damaging essential insurer-provider partnerships, potentially forcing higher reimbursement costs or network exits."
Claude, you're missing the second-order effect on provider relations. If insurers like UNH or CVS continue aggressive utilization reviews that delay oncology care, they risk alienating high-value hospital systems. Providers are increasingly shifting toward value-based care contracts where they share in the financial risk. If denials force providers to eat the cost of late-stage complications, they will demand higher reimbursement rates or abandon restrictive networks, directly pressuring insurer margins and long-term network stability.
"Granular denial-data by plan/region/indication and outcomes is essential; a pattern of guideline-concordant imaging under-approval could invite regulatory action and higher long-run costs, but outcome data is needed to prove systemic mispricing."
Grok’s claim about employer pushback shaping MA reform misses a key ambiguity: we don’t know if denials are guideline-based or improperly deprioritized. The panel should push for granular data: by plan, region, indication, and whether appeals succeed. The real risk is regulatory or political pressure if a pattern emerges that guideline-concordant imaging is systematically under-approved; but without clinical-outcome data, blaming insurers risks oversimplification and unintended access harm.
The panel agrees that high in-network denial rates for prior-authorized scans (19%) can lead to delayed diagnoses, increased long-term treatment costs, and potential regulatory pressure on insurers. The key debate lies in whether these denials are medically justified or profit-driven.
Improved data collection and transparency to distinguish between legitimate medical reviews and inappropriate denials.
Regulatory or political pressure if a pattern emerges that guideline-concordant imaging is systematically under-approved, potentially leading to unintended access harm.